Patents by Inventor Ana Isabel Jiménez Antón

Ana Isabel Jiménez Antón has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
    Patent number: 10011832
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: July 3, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
    Patent number: 10011837
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: July 3, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
    Patent number: 9808479
    Abstract: The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: November 7, 2017
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • siRNAs and Their Use in Methods and Compositions for the Treatment and/or Prevention of Eye Conditions
    Publication number: 20170058279
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Application
    Filed: March 4, 2015
    Publication date: March 2, 2017
    Applicant: Sylentis SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • siRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
    Publication number: 20150259677
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Application
    Filed: September 5, 2012
    Publication date: September 17, 2015
    Applicant: Sylentis SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • siRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
    Publication number: 20150224131
    Abstract: The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).
    Type: Application
    Filed: September 4, 2013
    Publication date: August 13, 2015
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • Treatment of CNS conditions
    Patent number: 8871729
    Abstract: Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: October 28, 2014
    Assignee: Sylentis, S.A.U.
    Inventors: Angela Sesto Yague, Eduardo Gomez-Acebo Gullon, Ma Concepción Jiménez Gomez, Ana Isabel Jiménez Antón
  • Modulation of TRPV expression levels
    Patent number: 8354385
    Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: January 15, 2013
    Assignee: Sylentis S.A.U.
    Inventors: Maria Del Carmen Acosta Boj, Juana Gallar Martinez, Angela Sesto Yague, Carlos Belmonte Martinez, Ana Isabel Jimenez Anton, Maria Concepcion Jimenez Gomez
  • Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
    Patent number: 8188057
    Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: May 29, 2012
    Assignee: Sylentis S.A.U.
    Inventors: Ana Isabel Jiménez Anton, Ángela Seso Yague, María Concepción Jiménez Gomez
  • MODULATION OF 11 BETA-HYDROXYSTERIOD DEHYDROGENASE 1 EXPRESSION FOR THE TREATMENT OF OCULAR DISEASES
    Publication number: 20110160277
    Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).
    Type: Application
    Filed: October 25, 2006
    Publication date: June 30, 2011
    Applicant: SYLENTIS S.A.U.
    Inventors: Ana Isabel Jiménez Anton, Ángela Sesto Yague, María Concepción Jimenez Gomez
  • MODULATION OF TRPV EXPRESSION LEVELS
    Publication number: 20100286230
    Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.
    Type: Application
    Filed: October 20, 2006
    Publication date: November 11, 2010
    Applicant: SYLENTIS S.A.U.
    Inventors: Maria del Carmen Acosta Boj, Juana Gallar Martinez, Angela Sesto Yague, Carlos Belmonte Martinez, Ana Isabel Jimenez Anton, Maria Concepcion Jimenez Gomez
  • Treatment of CNS Conditions
    Publication number: 20090176728
    Abstract: Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions.
    Type: Application
    Filed: March 16, 2007
    Publication date: July 9, 2009
    Applicant: SYLENTIS S.A.
    Inventors: Angela Sesto Yague, Eduardo Gomez-Acebo Gullon, Ma Concepción Jiménez Gomez, Ana Isabel Jiménez Antón